Stocks and Investing
Stocks and Investing
Mon, March 1, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Robert Burns Maintained (ALLO) at Strong Buy with Increased Target to $43 on, Mar 1st, 2021
Robert Burns of HC Wainwright & Co., Maintained "Allogene Therapeutics, Inc." (ALLO) at Strong Buy with Increased Target from $40 to $43 on, Mar 1st, 2021.
Robert has made no other calls on ALLO in the last 4 months.
There is 1 other peer that has a rating on ALLO. Out of the 1 peers that are also analyzing ALLO, 0 agree with Robert's Rating of Hold.
This is the rating of the analyst that currently disagrees with Robert
- Benjamin Burnett of "Stifel" Upgraded from Hold to Strong Buy and Increased Target to $43 on, Tuesday, January 26th, 2021
Contributing Sources